Evidence map›Paper›PMID 42049314›Full record

ArticleBMJ open2026

Efficacy of the serogroup B

Andreea Waltmann, Catherine Kronk, Dana Lapple, Michael P Motley, Feng-Chang Lin, Arlene C Seña, Marcia M Hobbs, Joseph A Duncan

Registry-linked trialAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05294588 (Division of Microbiology and Infectious Diseases,), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05294588 phase2completednot on this map

Division of Microbiology and Infectious Diseases, (DMID) 21-0018: Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae

TypeinterventionalSponsorUniversity of North Carolina, Chapel HillRan2022 to 2026Enrolled65ConditionsGonorrhea MaleArmsCefixime, Ceftriaxone, Ciprofloxacin, Neisseria gonorrhoeae strain FA1090, Meningococcal Group B Vaccine
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Andreea WaltmannDepartment of Medicine; Division of Infectious Diseases, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA.ORCID http://orcid.org/0000-0001-9219-6570
Catherine KronkDepartment of Medicine; Division of Infectious Diseases, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA.
Dana LappleDepartment of Medicine; Division of Infectious Diseases, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA.
Michael P MotleyDepartment of Medicine; Division of Infectious Diseases, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA.
Feng-Chang LinDepartment of Biostatistics, Gillings School of Global Public Health, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Arlene C SeñaDepartment of Medicine; Division of Infectious Diseases, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA.
Marcia M HobbsDepartment of Medicine; Division of Infectious Diseases, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA.
Joseph A DuncanDepartment of Medicine; Division of Infectious Diseases, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA Joseph_Duncan@med.unc.edu.

Funding

CTSA K12 Program at UNCK12TR004416 · NCATS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Michelle Hernandez, Jonathan J Juliano · 2023 to 2026
$6.5M
Efficacy of immunization with 4C-MenB in preventing experimental urethral infection with Neisseria gonorrhoeae.U01AI162457 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DUNCAN, JOSEPH A · 2021 to 2025
$3.9M
Planning the utilization of human challenge with Neisseria gonorrhoeae for vaccine testingR34AI148072 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DUNCAN, JOSEPH A, HOBBS, MARCIA METZGAR · 2020 to 2020
$233k
NCATS NIH HHS K12 TR004416NIAID NIH HHS R34 AI148072NIAID NIH HHS U01 AI162457
6 · The paper itself

Abstract

introductionRates of sexually transmitted infections are on the rise globally, including those caused by METHODS AND ANALYSIS: This is a double-blind randomised controlled trial testing the efficacy of the FDA-approved 4CMenB vaccine in preventing experimental ETHICS AND DISSEMINATION: All participants enrolled in the study provided informed consent twice. This study has been reviewed and approved by the University of North Carolina at Chapel Hill Institutional Review Board (#21-0498). Data collection for this study is ongoing. TRIAL REGISTRATION NUMBER: NCT05294588.

Indexed as

GonorrheaMeningococcal VaccinesNeisseria gonorrhoeaeNeisseria meningitidis, Serogroup BUrethritisAnimalsDouble-Blind MethodFemaleHuman Challenge Trials as TopicHumansMaleMiceRandomized Controlled Trials as Topic4CMenB vaccineMeningococcal VaccinesClinical ProtocolsClinical TrialSexually Transmitted DiseaseVaccination

Identifiers

PMID42049314
PMCPMC13141231

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.